Biogen and AbbVie Surpass Estimates Amid Mixed Pharmaceutical Sector Performance

Biogen reported first-quarter results that outperformed market expectations, fueled by the commercial scaling of its Alzheimer's treatment, Leqembi, leading BofA Securities to raise its price target to $203. Similarly, AbbVie's earnings surpassed estimates driven by robust sales in its immunology drug segment. Despite these positive financial results, Wall Street analysts expressed lingering concerns regarding long-term growth sustainability and market pressures. Biogen lowered its full-year profit guidance due to M&A-related costs, while maintaining its overall sales outlook. Investors remain focused on the adoption rates of new treatments as a key driver for offsetting competition in core segments. These developments highlight a period of cautious optimism across the pharmaceutical sector as major players navigate strategic pivots.